STOCK TITAN

IRIDEX (IRIX) SEC Filings, Jan-Feb 2026

IRIX NASDAQ

Iridex Corporation filings document an ophthalmic medical technology issuer whose disclosures center on laser systems, delivery devices, consumables, and procedure probes for glaucoma and retinal disease applications. Form 8-K reports furnish operating and financial results, preliminary results, Regulation FD investor materials, material agreements, and other material-event disclosures.

Proxy materials describe board matters, executive compensation, equity award valuation adjustments, and pay-versus-performance information. The filing record also includes Nasdaq continued-listing compliance updates, capital-structure context such as stockholders’ equity requirements, exhibits to press releases and presentations, and Inline XBRL cover-page data for formal Exchange Act reporting.

Rhea-AI Summary

IRIDEX Corp’s Chief Financial Officer, Romeo R. Dizon, reported an open-market purchase of common stock. On 02/10/2026, he acquired 1,000 shares of IRIDEX common stock at a price of $1.46 per share.

Following this transaction, Dizon directly beneficially owned a total of 116,190 shares of IRIDEX common stock. The filing indicates the ownership is held directly, and the Form 4 was signed on his behalf by attorney-in-fact Nilo De Castro.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.38%
Tags
insider
-
Rhea-AI Summary

IRIDEX Corp's Chief Financial Officer, Romeo R. Dizon, reported a stock purchase in a Form 4 filing. On 02/03/2026, he acquired 2,500 shares of IRIDEX common stock at a price of $1.38 per share. Following this transaction, he directly owns 115,190 common shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
insider
-
Rhea-AI Summary

IRIDEX Corporation’s Chief Financial Officer, Romeo R. Dizon, reported buying additional company stock. On January 29, 2026, he purchased 1,101 shares of common stock at $1.442 per share, bringing his directly held stake to 112,690 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
insider
Rhea-AI Summary

IRIDEX Corporation’s Chief Financial Officer, Romeo R. Dizon, reported an open-market purchase of company stock. On January 28, 2026, he bought 1,300 shares of common stock at $1.46 per share. Following this transaction, he directly owns 111,589 shares of IRIDEX common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.27%
Tags
insider
-
Rhea-AI Summary

IRIDEX Corporation’s Chief Financial Officer, Romeo R. Dizon, reported an open-market purchase of company stock. On 01/27/2026, he bought 3,385 shares of Common Stock at a price of $1.4799 per share, as shown by transaction code "P" for a purchase. Following this transaction, he beneficially owns 110,289 shares of IRIDEX Common Stock in direct ownership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
insider
-
Rhea-AI Summary

IRIDEX Corp Chief Financial Officer buys additional shares. On 01/26/2026, CFO Romeo R. Dizon purchased 1,243 shares of IRIDEX common stock at $1.52 per share in an open-market transaction coded "P" (purchase). After this trade, he directly owned 106,904 shares of IRIDEX common stock. This filing reflects a change in his personal share ownership and does not describe any change in the company’s operations or financial results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
insider
Rhea-AI Summary

IRIDEX Corporation’s Chief Financial Officer, Romeo R. Dizon, purchased additional shares of the company’s common stock. On 01/23/2026, he bought 5,221 shares at a weighted average price of $1.4779 per share, with individual trade prices ranging from $1.475 to $1.48. Following this purchase, he beneficially owns 105,661 shares of IRIDEX common stock in direct ownership. The transaction was reported as an open-market or private purchase, with full trade-level pricing details available upon request from the company, its security holders, or the SEC staff.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
insider
-
Rhea-AI Summary

IRIDEX CORP Chief Financial Officer Romeo R. Dizon reported open-market purchases of the company’s common stock. On January 20, 2026, he bought 2,100 shares at a price of $1.4987 per share. On January 21, 2026, he made two additional purchases of 409 shares at $1.53 per share and 1,750 shares at $1.49 per share.

After these transactions, Dizon directly owned 100,440 shares of IRIDEX common stock. The filing indicates these holdings are reported as directly owned, with no indirect ownership relationships noted.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.41%
Tags
insider
-
Rhea-AI Summary

Iridex Corp’s chief financial officer, Romeo R. Dizon, reported multiple acquisitions of the company’s common stock. On January 16, 2026, he acquired several small lots of shares at prices ranging from $1.38 to $1.45 per share, each coded as an acquisition transaction.

After these trades, his directly held beneficial ownership in Iridex common stock was reported at 96,181 shares. All reported holdings are shown as directly owned in his name.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.96%
Tags
insider
Rhea-AI Summary

IRIDEX Corporation reported that it has released preliminary, unaudited results for its fourth fiscal quarter and full fiscal year ended January 3, 2026. The company shared these operational and financial figures in a press release dated January 12, 2026, which is attached as Exhibit 99.1. The disclosure is being furnished rather than filed, meaning it is not automatically incorporated into other securities law filings unless specifically referenced.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.70%
Tags
current report

FAQ

How many IRIDEX (IRIX) SEC filings are available on StockTitan?

StockTitan tracks 98 SEC filings for IRIDEX (IRIX), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for IRIDEX (IRIX)?

The most recent SEC filing for IRIDEX (IRIX) was filed on November 17, 2026.